AAN 2021 | The impact of genetics in women with epilepsy
Kimford Meador, MD, FAAN, Stanford University, Stanford, CA, discusses the importance of precision medicine and improved biological understanding in women with epilepsy. A deeper knowledge of the impact of genetics on treatment effects and risks is critical to improving epilepsy management, particularly in relation to pregnancy. For example, the genotypes at risk for antiseizure medication-induced teratogenic deficits are not well understood. Substantial variability in neurodevelopmental outcomes in children of women with epilepsy suggests many other factors may impact pregnancy outcomes and further investigation is needed. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Grants: NIH/NINDS 2U01-NS038455-11A1. Meador (Multi-PI). “Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs.”*
NIH/NINDS R01NS088748-01. Drane (PI). “Dissecting the Cognitive Roles of Hippocampus & Other Temporal Lobe Structures.” Role: Co-I.
Medtronics. Halpern (PI). “Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE).” Role: Co-I.
Eisai Inc. Razavi (PI). “Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures.” Role: Co-I.
Sunovion Pharma. Meador (PI). “Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults.”
Consultant (no personal income): Epilepsy Consortium (funds paid to my university)* for Eisai, GW Pharmaceuticals, Medtronics, NeuroPace, Novartis, Supernus, Upsher Smith Labs, UCB Pharma, and Vivus Pharm.
Other: Clinical income: EEG procedures and patient care*
*Items with asterisk involve income > $10,000 for recent years.
